A Real-world Study to Explore Recurrence/Metastases of the Early-stage (I-IIIA) NSCLC Patients and the Impact Factors of Patient Survivals
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Non-small Cell Lung Cancer
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Enrollment
- 700
- Locations
- 1
- Primary Endpoint
- Disease-free survival rates within the configured observation periods
- Last Updated
- 6 years ago
Overview
Brief Summary
The real-world study was designed to explore recurrence/metastases of the patients with non-small cell lung cancer as measured by patient survivals and the impact factors of patient survivals.
Detailed Description
The trial was designed as a real-world observational study to recruit those patients with pathologically diagnosed early-phase non-small cell lung cancer (NSCLC) who were enrolled in the clinical form 2009 to 2017 and explore recurrence/metastases of the NSCLC patients as measured by patient survivals and the impact factors of patient survivals. The study data on patient demographic characteristics, tumor biological characteristics, and clinicla treatments were collected via a retrospectively review method for evaluation of patient survivals and the relevance of clinical characteristics of the patients and patient survivals.
Investigators
Jianxing He
Professor
The First Affiliated Hospital of Guangzhou Medical University
Eligibility Criteria
Inclusion Criteria
- •The patients who meet all the following inclusion criteria will be included in the study:
- •The patients who were operated with radical operations of the lung cancer;
- •The patients with clinical I-IIIA staging tumors;
- •The pathologically diagnosed NSCLC patients;
Exclusion Criteria
- •Not be specified;
Outcomes
Primary Outcomes
Disease-free survival rates within the configured observation periods
Time Frame: 2009-2017
Disease-free survival rates within 3-month, 6-month, 1-year, 2-year, and 3-year observation periods;
Secondary Outcomes
- Disease-free survival rates at the configured locations and observation periods(2009-2017)